Cleveland BioLabs, Inc. (CBLI)

4.0300 +0.2900 (+7.75%) At close: 4:00PM EST

Cleveland BioLabs, Inc.

73 High Street
Buffalo, NY 14203
United States
716 849 6810
http://www.cbiolabs.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 7

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Christopher Zosh	VP of Fin., Interim Principal Exec. Officer, Principal Financial Officer & Accounting Officer	103.49k	N/A	1975
Dr. Andrei V. Gudkov	Chief Scientific Officer	66.14k	N/A	1956
Dr. Langdon L. Miller	Chief Medical Officer	73.72k	N/A	1954

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.

Corporate Governance

Cleveland BioLabs, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.